Based on 12612 reference(s) in Google Scholar 8 10 12612

Axon 3324

CAS [50-35-1]

MF C13H10N2O4
MW 258.23

  • Purity: 99%
  • Soluble in DMSO



Thalidomide was initially promoted as a sedative with anti-emetic properties. Later, Thalidomide was shown to have immunomodulatory and anti-inflammatory properties in erythema nodosum leprosum (ENL). Moreover, Thalidomide was found to inhibit fibroblast growth factor (bFGF)-induced formation of new blood vessels. Thalidomide targets the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and promotes the ubiquitination of Ikaros/Aiolos transcription factors by CRL4CRBN.

KEYWORDS: Thalidomide | supplier | TNFα inhibitor | CAS [50-35-1] | TNF-α | CD120 | Inhibitor | Receptors | Multiple myeloma | Leprosy | Erythema nodosum leprosum | Anti-angiogenic cancer

Size Unit Price Stock
50 mg €50.00 In Stock
Special Offers
Size Unit Price Stock
2 x 50 mg €70.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...